SLXN
NASDAQ HealthcareSilexion Therapeutics Corp - Ordinary Shares
Biotechnology
Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. Silexion Therapeutics Corp has collaboration with Evonik Corporation for the development of an advanced siRNA formulation to enhance cancer treatment. The company was founded in 2008 and is headquartered in Jerusalem, Israel.
�� 市场数据
| 价格 | $0.44 |
|---|---|
| 成交量 | 26,834,702 |
| 市值 | 2.42M |
| 贝塔系数 | -0.360 |
| RSI（14日） | 52.9 |
| 200日均线 | $10.37 |
| 50日均线 | $1.22 |
| 52周最高 | $42.60 |
| 52周最低 | $0.32 |
| Forward P/E | -0.68 |
| Price / Book | 54.44 |
🎯 投资策略评分
SLXN 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🔪 Falling Knife (99/100) — 此策略 逆向投资（超卖 + 低于移动均线）.
评分最低的策略： 🚀 Moon Shot (1/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 SLXN in your text
粘贴任何文章、记录或帖子 — 工具将提取 SLXN 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-09-18.